To say that a cure for ovarian cancer, or any cancer for that matter, is the “holy grail” of cancer research is like saying the sky is blue. We all know a cure is the goal. If a cure is the goal, then improved detection, new prevention methods, and new treatments are the low-hanging fruit. […]
Read More
The Rivkin Center is proud to announce that we have awarded $810,000 in ovarian cancer research grants to nine scientists across the globe.
Read More
PARP inhibitors represent an important new class of anticancer agents that are having a major impact on ovarian cancer treatment. These drugs target vulnerabilities in DNA damage response and repair pathways especially in cancer cells that have defects in BRCA and related genes. In an important clinical development announced April 6, 2018, the FDA expanded […]
Read MoreDr. Rivkin and I attended the annual meeting of the American Society of Clinical Oncology (ASCO)—a gathering of 38,000 oncology experts from all over the world—in early June in Chicago, Illinois. In addition to oncologists, the attendees included researchers, educators, advocates, research funders, survivors and representatives from genetic testing, drug and other services companies. Our […]
Read More